Bivatuzumab mertansine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Bivatuzumab mertansine
Mertansine mab structure.svg
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD44 v6
Clinical data
ATC code
  • none
  • none
 NYesY (what is this?)  (verify)

Bivatuzumab mertansine is a combination of bivatuzumab, a humanized monoclonal antibody, and mertansine, a cytotoxic agent. It is designed for the treatment of squamous cell carcinoma.[1]


  1. ^ Tijink, BM; Buter, J; De Bree, R; Giaccone, G; Lang, MS; Staab, A; Leemans, CR; Van Dongen, GA (2006). "A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus". Clinical Cancer Research. 12 (20 Pt 1): 6064–72. PMID 17062682. doi:10.1158/1078-0432.CCR-06-0910.